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Abstract—During the last three decades, several laser sys-
tems, ancillary technologies, and treatment modalities have
been developed for the treatment of port wine stains (PWSs).
However, approximately half of the PWS patient population
responds suboptimally to laser treatment. Consequently,
novel treatment modalities and therapeutic techniques/strat-
egies are required to improve PWS treatment efﬁcacy. This
overview therefore focuses on three distinct experimental
approaches for the optimization of PWS laser treatment. The
approaches are addressed from the perspective of mechanical
engineering (the use of local hypobaric pressure to induce
vasodilation in the laser-irradiated dermal microcirculation),
optical engineering (laser-speckle imaging of post-treatment
ﬂow in laser-treated PWS skin), and biochemical engineering
(light- and heat-activatable liposomal drug delivery systems
to enhance the extent of post-irradiation vascular occlusion).
Keywords—Vascular malformations, Dermis, Suboptimal
therapeutic response and lesional recalcitrance, Hypobaric
pressure, Suction cup, Blood ﬂow, Laser speckle imaging,
Site-speciﬁc pharmaco-laser therapy, Liposomal drug deliv-
ery system.
INTRODUCTION
Port wine stains (PWSs) are congenital vascular
lesions characterized by hyperdilated microvasculature
predominantly in the upper dermis. Due to the high
blood content in the hyperdilated blood vessels, the af-
fectedregionoftheskinappearsred-to-purple(Fig. 1a).
The color intensity of the lesions typically worsens with
age and, when left untreated, approximately two-thirds
of the lesions develop nodular components and facial
deformity.
44,55,59,106 Apart from being a cosmetic
problem with often considerable psychosocial ramiﬁ-
cations for the patient,
86 some lesions present with
ocularandneurologicaldisorderssuchasglaucomaand
seizures, respectively.
136 Consequently, a strong need
exists to optimally treat PWSs.
The standard treatment of PWSs entails laser irra-
diation of the aﬀected portions of the skin (Fig. 1b) in
accordance with the theory of selective phototherm-
olysis (SP).
7 Laser irradiation leads to photocoagula-
tion of the hyperdilated blood vessels, which in turn
results in their removal and subsequent clearance of
the PWS.
64 Clinical studies have shown that complete
photocoagulation of the vascular lumen is associated
with complete lesional clearance, and that partial
photocoagulation is associated with suboptimal
responsiveness.
48,60,72,137 Therefore, the key to effec-
tively treating recalcitrant lesions is the complete
(photo)occlusion of PWS vasculature.
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486Unfortunately, the clinical reality is that laser ther-
apy is eﬀective in approximately half of PWS patients
(Fig. 1c).
1,5,11,12,20,27,32,34,41,53,56–58,70,71,79,80,83,
84,88,90,
109,110,113,124,130,133,144,159,160 This overview therefore
focuses on the causes of the therapeutic recalcitrance
and presents several experimental engineering
approaches, including (1) alterations in local hemody-
namics, (2) concomitant laser treatment and dermo-
vascular imaging, and (3) site-speciﬁc pharmaco-laser
therapy, with which the therapeutic efﬁcacy of
recalcitrant PWSs may be improved.
ENDOVASCULAR LASER–TISSUE
INTERACTIONS
Selective Photothermolysis
Selective photothermolysis is a non-invasive laser
treatment modality that relies on the conversion of
radiant energy to heat by (oxy)hemoglobin and the
ensuing coagulation of blood and necrosis of (peri)vas-
cular tissue resulting from thermal diﬀusion
(Fig. 2a).
7,15,19,21,22,107,150 By irradiating skin at a well-
absorbed wavelength and sufﬁcient irradiance (the
amountofphotonenergyincidentonaunitareaoftissue
per unit time, expressed in W/cm
2), supracritical tem-
peratures(>70  C)canbegeneratedinthevessellumen
andconﬁnedspatiallyifthepulsedurationiskeptwithin
thethermalrelaxation time ofthetargetblood vessel or,
in case of large-diameter vasculature, the volume of
blood in which the radiant energy is absorbed. Thermal
relaxationtimeisdeﬁnedasthetimerequiredforheated
matter to lose 50% of its peak thermal energy through
thermal conductivity.
7,147 The ideal pulse duration for
blood vessels of 20–150 lm has been shown to range
from 1 to 10 ms.
39 Normal-sized capillaries (4–6-lm
inner diameter) and post-capillary venules (8–26-lm
inner diameter),
24 which have relatively short thermal
relaxation times and a smaller volume-to-surface ratio
(thermal mass), therefore remain spared during longer
pulse durations, as heat diffusion from these vessels
precludes the generation of denaturing temperatures.
FIGURE 1. (a) Image of a facial PWS, accompanied by soft tissue overgrowth in the mouth area. The encircled portion of the
patient’s PWS is enlarged in (b) and presented as a cross section. The various layers of the skin are indicated. The dermis is replete
with microcirculation, whereby the arterial segment of the vasculature is depicted in red and the venular segment in blue. Hy-
perdilation of blood vessels in PWSs prevails predominantly in the venular segment. PWSs are treated non-invasively with lasers
(probe), most frequently with pulsed dye lasers (PDLs) in the 577–600 nm range or Nd:YAG lasers (1064 nm or its second har-
monic, 532 nm) because of the preferential absorption by hemoglobin. The laser beam signiﬁcantly diverges in the skin because of
scattering. In (c), a summary is provided of clinical studies published between 1990 and 2010, in which the clinical outcome was
scored in accordance with the legend (‘‘degree of PWS clearance’’). The y-axis indicates the percentage of patients, the x-axis lists
the clinical studies by their respective reference. The study outcomes are presented vertically, where each bar represents a
grayscale-coded stratum according to the legend. The studies were categorized by laser modality, separated by the vertical red
lines and yellow tabs in the chart. The blue line corresponds to the percentage of patients at which the median treatment outcome
was reached, i.e., the percentage of patients in which 0–50% clearance (black + dark gray bars) was achieved. This line reﬂects the
treatment efﬁcacy over the sampling period, showing that improvement in PWS therapy is needed and that the degree of lesional
clearance does not necessarily depend on the laser modality. Studies with deviant scoring system: references 15, 17, 24 (0–75%
clearance 5 black, 76–100% clearance 5 white), references 18, 20, and 37 (0–50% clearance 5 black, 51–100% clearance 5 white).
PDL 5 pulsed dye laser, DC 5 dynamic cooling, IPL 5 intense pulsed light. Image of skin and vascular anatomy courtesy of Ms.
Libus ˇe Markvart.
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induced production of supracritical temperatures leads
to thermal necrosis of the vascular wall and vaso-
occlusion by thermolysed and agglutinated erythro-
cytes.
19,21,48,72,137,138 The putative contention is that
the photocoagulated vessels are removed by the
reticulo-endothelial system and replaced by normal-
sized capillaries through vascular remodeling
(Fig. 2b).
64,76,116 Replacement of hyperdilated vessels
with lower blood volume-containing capillaries is
associated with a reduction in PWS redness (Fig. 2c),
which marks the therapeutic end point. Clinically,
complete photocoagulation of the vascular lumen is
associated with well-responding lesions,
48 correspond-
ing to approximately 40% of the cases.
60 In contrast,
moderately responding (20–46%) and refractory
(14–40%) PWSs have an acute post-treatment damage
proﬁle characterized by varying degrees of partially
photocoagulated vessels with semi-obstructive thermal
coagula.
48,72,137
Causes of Therapeutic Recalcitrance
The eﬃcacy of SP depends on a combination of
inevitable intrinsic factors, including epidermal pig-
mentation,
36,80,146,153 optical shielding by blood and
superimposed vessels,
47,48,72,92,117,137 and vascular
anatomy and morphology.
47,48,72,117,149,154 In general,
treatment efﬁcacy correlates negatively with increased
melanin content, vascular density and superimposition,
and vessel diameter and depth, given that the promi-
nence of these factors is inversely proportional to the
optical penetration depth. Inasmuch as the optical
penetration depth, and thus the ﬂuence rate (/, the
FIGURE 2. (a) Endovascular laser–tissue interactions in relation to SP. When an erythrocyte-ﬁlled blood vessel (1, red
spheres 5 erythrocytes) is irradiated with a laser (2, hv) at a wavelength that is predominantly absorbed by hemoglobin in the
erythrocyte (3, left panel), the radiant energy is converted to heat (3, blue arrows left panel) that subsequently diffuses away from
the erythrocyte. The biomolecules (DNA, proteins, and lipids) in the regions of supracritical heating (>70  C) undergo thermal
denaturation (photocoagulation), as a result of which cells and structures lose their native physicochemical properties (3, right
panel). Blood undergoing photocoagulation forms a thermal coagulum—an amorphous clump of damaged and agglutinated
erythrocytes and plasma constituents—with which the vascular lumen becomes occluded (4). The extent to which PWS vascu-
lature is photocoagulated during laser treatment essentially dictates the biological response to SP, outlined in (b). The putative
contention is that complete photo-occlusion (top pathway) most often results in vascular remodeling characterized by removal of
the thermally afﬂicted vasculature followed by limited angiogenesis and/or neovasculogenesis. These processes typically result in
good clinical clearance inasmuch as the dermal blood content is considerably reduced after the vascular remodeling phase
(‘‘clinical outcome’’ panel, illustrating the changes in skin color before (left) and after (right) treatment). Alternatively, when
angiogenic/neovasculogenic remodeling following laser treatment is extensive, sufﬁcient reduction in dermal blood volume is
hampered and only mild clearance is achieved (middle pathway). In other instances, particularly in refractory PWSs, light pene-
tration is insufﬁcient to induce complete photocoagulation of the vascular lumen, resulting in partial occlusion of the target vessel
by a thermal coagulum (bottom pathway). During the remodeling phase, the thermal coagulum is either removed by the reticu-
loendothelial system or becomes part of the vascular wall, leading to luminal thinning (small opposing arrows). This damage
proﬁle is associated with minimal reduction in dermal blood volume and hence poor clinical outcome.
AGUILAR et al. 488amount of photon energy incident on a unit area inside
tissue per unit time, expressed in W/cm
2) attenuates
with depth in accordance with Beer’s law, scattering,
and (specular) reﬂection,
114,149 the volumetric heat
production (/ Æ la, where la is the absorption coefﬁ-
cient) in blood vessels located beyond a certain depth
will be inadequate for the complete photocoagulation
of the vascular lumen.
Port wine stain vessels have been found in the
reticular plexus up to a depth of 3.7 mm,
139,145 albeit
most of the ectatic vasculature is located within
~0.6 mm from the basal membrane.
14,72 Theoretically,
complete lesional clearance can only be accomplished
when the optical penetration depth equals or exceeds
the depth up to which the ectatic vasculature is
responsible for the visual appearance of the PWS.
Mathematical modeling predicted this depth to be 0.6–
0.9 mm at which hyperdilated vessels contribute to the
skin discoloration.
85,153 Histological studies have re-
vealed that photocoagulation occurs to a depth of
~0.65 mm in human skin using 585-nm wavelength
and 0.45-ms pulse duration, with a mean ± SD depth
of 0.37 ± 0.17 mm.
48,72 At these laser parameters (and
a radiant exposure of 6.5 J/cm
2106), complete coagu-
lation of the vessel lumen occurs in superﬁcial vessels
up to approximately 150 lm in diameter.
72 Larger and
deeper vessels will therefore remain (partly) patent, as
has been corroborated histologically and numeri-
cally.
92,152 In the context of the model predictions,
these ﬁndings explain why some PWSs are non-
responsive to treatment at the abovementioned laser
parameters based on depth alone.
With respect to optical penetration, it is not surpris-
ing that the diﬀerence between the irradiance and the
ﬂuence rate becomes even more pronounced with depth
in densely vascularized areas
92,114,155 and in skin types
with a higher melanin concentration
72,154 and dermal
blood volume.
154 Consequently, incomplete photoco-
agulation of target vessels may result from the genera-
tion of subcritical isotherms (<70  C) because of
inhomogeneous photon deposition in the lumen (as is
the case with large diameter vessels), or may be fore-
stalled altogether by insufﬁcient heat production across
the entire vessel diameter, such as in deeply situated or
optically shielded vessels. Differences in intralumenal
ﬂuence rates due to the abovementioned factors there-
fore have a profound effect on the acute and chronic
tissular responses (Fig. 2b), and thus lesional clearance.
HEMODYNAMIC ALTERATIONS IN THE
DERMIS
Rather than attempting to bring more light to the
blood, which has yielded little clinical improvement
over the past 20 years (Fig. 1c), more blood could be
brought to the already available light to optimize the
extent of laser-mediated photocoagulation. Several
premises lie at the basis of systematically inducing
hemodynamic alterations in the PWS dermis through
the local application of hypobaric pressure. First, the
venules in mild red or faint PWSs have an average
diameter of 10–30 lm,
115 and hence a thermal relaxa-
tion time that is shorter than the 0.5–1.5-ms pulses
emitted by most pulsed dye lasers.
7 Consequently, the
target vessels are difﬁcult to photocoagulate by SP
because the volumetric heat production is insufﬁcient
to adequately heat the entire vascular lumen. Second,
smaller vessels have a lower erythrocyte concentration
and thus less chromophore to generate supracritical
temperatures required for complete photocoagulation
of the vascular lumen. A recent clinical study,
18 where
PWS treatment was performed with an intense pulse
light system, revealed that it was difﬁcult to photoco-
agulate vessels of <60 lm in diameter at radiant
exposures of <30 J/cm
2. These ﬁndings were attrib-
uted to insufﬁcient heat generation in the vascular lu-
men because of the low hemoglobin concentrations in
the small-diameter vessels. Third, small-diameter ves-
sels also have a lower thermal mass, as a result of
which heat dissipation into perivascular tissue (i.e.,
cooling) proceeds faster than in larger vessels.
Accordingly, the augmentation of venular diameters
through the application of hypobaric pressure will
temporarily synchronize the thermal relaxation time of
these vessels with the standardized pulse durations
employed and concomitantly increase intravascular
chromophore content and thermal mass.
Proposed Mechanism of Vacuum-Induced Vasodilation
The vacuum-induced pressure gradient across a
vessel is not the main cause of its dilation, but rather
the body’s physiological response to locally applied
pressure. Vasoactivity in the cutaneous microcircula-
tion is partly controlled by the body’s systemic mech-
anisms, i.e., by cardiac output, the amount of
resistance imposed by the arteries/arterioles, and by
varying the amount of blood that is pooled within the
veins/venules.
35 The latter two aspects are in turn
regulated by vasoactive substances secreted into the
circulation and by vasomotor nerves that innervate the
mural tissue of arterioles.
Local vasoactivity of arterioles and venules depends
on the balance between plasma concentrations of
vasodilators [nitric oxide (NO), prostacyclin, carbon
monoxide], and vasoconstrictors (endothelin-1, throm-
boxane A2). These compounds are secreted by proxi-
mal cells such as endothelial cells that line the lumen of
blood vessels.
52 Of these, NO acts directly on pericytes
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Endothelial cells further respond to stimuli such as
ﬂow changes, stretching, and shear stress, whereby the
latter triggers the release of NO.
33,40,111 When suction
is applied to a localized region on the skin surface, it is
believed that the endothelial cells exposed to the
mechanical strain and stress release NO that in turn
triggers the vasodilation.
Physical and Tissular Eﬀects of Hypobaric Pressure
on Skin
A hypobaric pressure-modulatable device has been
developed to locally increase vascular diameters in
PWS skin (Fig. 3a). Several investigations on this de-
vice have employed numerical models in combination
with experimental work to characterize and validate
hypobaric pressure-related predictions and hypotheses.
With respect to the mechanical effects of local vacuum
on skin, Childers et al.
29 developed a macroscopic
model comprising classical structural mechanics
equations solved by ﬁnite element methods to compute
the extent of lateral stretching and axial displacement
of PWS skin in a suction cup. The predictions were
juxtaposed to experimental data obtained by video
imaging of vacuum-deformed skin, demonstrating
excellent agreement between the computed and mea-
sured deformations (Fig. 3b).
29
The stress–strain ﬁeld computations by Childers
et al.
29 subsequently served as a boundary condition
for the development of a model to determine the
microscopic thinning of the epidermis, the axial dis-
placement of a simulated blood vessel, and its dilation.
The model predicted (1) epidermal thinning of 6 lma t
maximum hypobaric pressure (50 kPa, 381 mmHg),
(2) a 2.5-lm displacement of a typical blood vessel at
250 lm below the skin surface, and (3) only a 5%
dilation of this vessel at the indicated pressure.
The extent of vasodilation as determined by Chil-
ders et al.
29 was rather disproportionate to the
underlying hypothesis of vacuum-induced vessel dila-
tion and in contrast with subsequent theoretical/
empirical ﬁndings. For instance, visible reﬂectance
spectrometry measurements on vacuum-treated PWS
skin provided indirect evidence for vacuum-induced
changes in vascular diameter that, based on a light
diffusion approximation model, encompassed a two-
fold dilation and a 10% increase in the blood volume
fraction (BVF) at 250 kPa (381 mmHg).
134 The 5%
vessel dilation predicted by Childers’ microscopic
model
29 corresponded to a mere 0.3% increase in the
BVF, which lies below the limit of detection of visible
reﬂectance spectrometry. It was further shown that,
during the ﬁrst 0.5 s of vacuum application, the skin
underwent a reduction in BVF and vessel diameter
(Dv), while the bulk tissue was being deformed by the
suction. After this time interval, however, both BVF
and Dv rose from 1.3 to 10.5% and from 9.5 to
20.0 lm, respectively, reaching a plateau after ~9s
(Fig. 3c).
3,29,49 Moreover, the kinetics of BVF and Dv
during the application of hypobaric pressure were
characterized by a fast rate increase followed by a
slower rate increase. The initial increase in BVF and Dv
was likely driven by predominately biochemically
mediated muscle relaxation, whereas the subsequent
(lower rate) increase in BVF and Dv was likely driven
by the mechanical strain applied to the vessel wall after
the smooth muscle cells had fully relaxed.
Eﬀects of Hypobaric Pressure on Cutaneous
Laser Treatment
Hypobaric pressure does not only induce vasodila-
tion but exerts several other eﬀects that are beneﬁcial
for the laser treatment of PWSs. Franco et al.
49 em-
ployed a numerical model of light and heat diffusion
that yielded three important aspects of laser–tissue
interactions at hypobaric pressure. First, hypobaric
pressure causes less radiant energy to be absorbed in
the epidermis because the stretching of the skin reduces
epidermal thickness and the concentration of melanin
per unit area. Second, more light is delivered to an
increased blood volume, as a result of which higher
intralumenal temperatures can be generated. The ex-
tent of volumetric heat production in the lumen is
proportional to the amount of hypobaric pressure
applied (Fig. 3d). Third, the higher energy deposition
in a larger blood volume was found to correlate to the
induction of higher temperatures in all vessel sizes,
although the temperature increases in 10–30-lm
diameter vessels were more signiﬁcant (Figs. 3e and
3f). This exacerbates the degree of irreversible thermal
damage to small, recalcitrant PWS vasculature, while
keeping other blood vessels relatively intact.
Corroboratively, Yeo et al.
163 demonstrated in
ex vivo porcine skin that the peak intensity of the
incident laser photon density increased 3.6-fold when
used in combination with hypobaric pressure at 30 kPa
(254 mmHg). These effects were attributed to tissue
thickness reduction and water content loss as a result
of the mechanical stretching/compression of skin. The
vacuum-induced deformation of skin further decreases
the effective distance between adjacent chromophores
(i.e., blood vessels) as well as the distance between
elastin layers. Those authors therefore hypothesized
that these phenomena improve refractive index
matching and that, consequently, the increase in laser
photon density in tissue could potentially improve the
therapeutic efﬁcacy for PWS.
AGUILAR et al. 490Eﬀects of Hypobaric Pressure on Cryogen Spray
Cooling Dynamics
Epidermal pigmentation (melanin) constitutes the
most important ﬂuence-limiting factor in the laser
treatment of PWS. Melanin absorption at the clinically
employed pulsed dye laser wavelengths is greater than
hemoglobin absorption, as a result of which a balance
has to be struck between optical penetration depth and
the maintenance of subcritical temperatures at the
stratum basale—the deepest epidermal layer contain-
ing the melanocytes. This balance is governed by the
employed laser settings (wavelength, pulse duration,
FIGURE 3. (a) An example of a suction cup that is used to induce local hypobaric pressure on the skin. (b) Image of bulk tissue
deformation on the forearmof a subject exposed to 34 kPa (247 mmHg)of hypobaric pressure (rightpanel) and the skindeformation
proﬁle as computed by a structural mechanics model
29 at the same hypobaric pressure (left panel). (c) Small-scale numerical model
and visible reﬂectance spectroscopy results reﬂecting changes in blood ﬂow velocity (BVF) and average vessel diameter (Dv)a sa
function of time during the application of 50-kPa hypobaric pressure on the palm of a 24-year-old male. Data modiﬁed from Aguilar
et al.
3 (d) Numerical analysis of temperatures (y-axis) generated at the end of a laser pulse (585-nm wavelength, 0.45-ms pulse
duration, 1-J/cm
2106 radiant exposure, 10-mm spot size) at different dermal depths (x-axis) in Fitzpatrick type II skin, plotted for
increasing local hypobaric pressures. A 10-lm-diameter blood vessel was positioned at 200 lm below the skin surface. Data taken
from Franco et al.
49 Differences in blood (e) and vessel wall temperatures (f) at the end of the laser pulse (585-nm wavelength, 0.45-
ms pulse duration, 1-J/cm
2 radiant exposure, 10-mm spot size) at hypobaric and atmospheric pressures, plotted as a function of
vessel diameter for different vessel depths (legend). Fitzpatrick skin type 2 was modeled. Data taken from Franco et al.
49
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considerable photocoagulation of PWS vasculature
but thermally aﬄict the epidermis, while too low ﬂu-
ences result in incomplete photocoagulation but pre-
serve epidermal integrity. By the application of
epidermal cooling technologies, the balance can be
shifted in favor of the optical penetration depth by
controlling the extent of heat generation at the stratum
basale during a laser pulse.
The most common epidermal cooling techniques
include 1,1,1,2-tetraﬂuoroethane (R134a)-mediated
cooling, commonly referred to as cryogen spray cool-
ing (CSC), contact cooling,
6 and cold air cooling.
122 In
the mid-90s, several proof-of-concept studies demon-
strated that CSC was effective in protecting normal
skin
9 and PWS skin epidermis
9,105 from high-irradi-
ance laser pulses. Subsequent infrared radiometric
experiments showed that CSC-induced temperature
reductions can be conﬁned to the upper ~200 lmo f
skin (i.e., the average thickness of facial epidermis),
8
allowing epidermal cooling without affecting the extent
of vessel photocoagulation. Also, the heat ﬂux and
total energy removed per unit skin surface area were
shown to be at least doubled when using CSC vs.
alternative cooling methods such as contact cooling.
8
Consequently, CSC has become the most studied and
implemented cooling technique in dermatological laser
applications, particularly for shallow targets such as
PWS vasculature.
The use of hypobaric pressure not only entails the
previously mentioned advantages for PWS laser ther-
apy (‘‘Effects of Hypobaric Pressure on Cutaneous
Laser Treatment’’ section) but also facilitates a more
efﬁcacious epidermal cooling protocol in a number of
ways. First, recent studies evinced that, under hypo-
baric pressures, evaporating sprays such as R134a have
a larger adiabatic expansion,
2 which means that their
saturation or evaporating temperature is reduced under
vacuum conditions. With respect to R134a, the evap-
oration temperature at atmospheric pressure is roughly
226  C.
134 The evaporation temperature of R134a can
be reduced in a hypobaric pressure-dependent fashion
(Fig. 4a), up to 15  Ca t251 kPa (381 mmHg) vs.
atmospheric pressure, by releasing the CSC spurt
within a small vacuum chamber or suction cup. This
was further elaborated by Aguilar et al.
2 through sys-
tematic measurements of skin phantom surface tem-
perature variations and heat ﬂuxes for spurts delivered
at increasing hypobaric pressures. The extent of surface
cooling was proportional to the extent of hypobaric
pressure at equivalent CSC settings (Fig. 4b), with the
difference in the minimum surface temperature reach-
ing as high as 20  C in the 67-kPa (508 mmHg) hypo-
baric pressure group vs. the atmospheric pressure
group. Similarly, the degree of CSC-mediated heat
extraction from the skin phantoms correlated positively
with the magnitude of hypobaric pressure (Fig. 4c).
The observed effects are attributable to the larger
pressure-induced expansion of the CSC spurt (see next
paragraph) and larger temperature differential between
the cryogen and skin phantom surface temperature
with increasing hypobaric pressures (Fig. 4a).
In terms of spray atomization, i.e., the fragmenta-
tion of ﬂuids into drops, it was demonstrated that
higher droplet velocities are associated with better
atomization and, consequently, a more homogeneous
cryogen spray deposition due to the larger pressure
diﬀerential across the spray nozzle.
2 Light reﬂection
experiments revealed that the ‘‘jet length,’’ or the dis-
tance a core jet of cryogen travels before atomizing
into smaller droplets, was signiﬁcantly reduced at
lower pressures in the expansion chamber (Fig. 5a).
Third, under atmospheric conditions the spray
impingement on the skin may produce an indented
FIGURE 4. (a) Pressure–temperature (P–T) diagram for 1,1,1,2-tetraﬂuoroethane (R134a), showing reduced saturation (i.e.,
evaporation) temperatures with increasing hypobaric pressure (designated in mmHg and indicated in light gray). AP 5 atmo-
spheric pressure. (b) Skin phantom surface temperatures as a function of time after initiation of a CSC spurt for 0 (AP), 127, 254,
381, and 508 mmHg of hypobaric pressure. (c) Skin phantom surface heat removal as a function of time for 0 (AP), 127, 254, 381,
and 508 mmHg of hypobaric pressure. Q 5 total heat extraction.
AGUILAR et al. 492(concave) surface as deep as 2 mm,
16 which decreases
the maximum heat ﬂux across the skin surface by as
much as 30% relative to a ﬂat surface. Contrastingly,
local hypobaric pressure induces the formation of a
convex surface (Fig. 5b), which abrogates the CSC
spurt-induced indentation and minimizes cryogen
‘‘pooling’’ and thus decreases the adverse heat ﬂux.
Finally, inasmuch as the air with a standard relative
humidity is depleted at hypobaric pressures, the
humidity within the chamber is signiﬁcantly dimin-
ished. This eﬀect in itself results in an enhancement of
heat extraction from the skin, as documented by Tor-
res et al.,
143 Majaron et al.,
93 and Ramirez-San-Juan
et al.
120 and prevents the build up of frost during a
CSC spurt in the absence of a suction device because of
the condensation and freezing of surface moisture on
the skin. Frost formation and the evaporation of the
cryogen pool are associated with reduced optical pen-
etration depth
43,120 and thus subtherapeutic photoco-
agulation. Moreover, frost formation may result in
overcooling of the skin and corollary (epi)dermal
injury.
38,77,119
Overall, the combined eﬀects of hypobaric pressure
on CSC such as reduced spray temperature, better
atomization and spray deposition, enhanced evapora-
tion rate, stretched and convex skin surface, and lower
local humidity result in a reduced skin surface tem-
perature and an improvement in the overall heat
extraction provided by CSC.
COMBINED LASER TREATMENT
AND OPTICAL IMAGING
During the past three decades, experimental studies
have focused on the development of methods to im-
prove the eﬃcacy of each PWS treatment session so as
to reduce the total number of required sessions. Pre-
vious theoretical studies have established optimal laser
parameters for treatment of model PWS blood vessels.
However, PWS vascular anatomy and morphology is
highly heterogeneous in a single lesion, as a result of
which every singularly treated dermal volume essen-
tially requires its unique set of laser parameters.
Accordingly, the general consensus is that pretreat-
ment knowledge of PWS skin characteristics could be
used to guide laser parameter selection on a person-
alized basis
148 so as to treat the entire PWS more
effectively.
Considerable research eﬀort has been invested in the
noninvasive characterization of PWS skin regions and
the quantiﬁcation of skin characteristics such as blood
vessel diameter and depth.
31,94,95,100,104,151,156 Cur-
rently, the novel instrumentation under development is
limited due to the inherent complexity of PWS micro-
vascular architecture
126,132 and the lack of knowledge
on how exactly the extracted skin characteristics can be
used to guide treatment parameter selection.
In an eﬀort to establish a relationship between
diagnostic/prognostic optical techniques and laser–
FIGURE 5. Isolated video frames of CSC spurts released within a vacuum chamber under atmospheric pressure (a, 760 mmHg)
and at 254 (b), 381 (c), and 508 mmHg (d) of hypobaric pressure. The frames were isolated at 100 ms into a 1-s CSC spurt. Arrows
indicate approximate jet length based on the region of intense light reﬂection. The inserts are representations of droplet distri-
bution for the respective CSC spurt. The images in panels (a–d) were converted to binary images and a grayscale intensity
threshold cutoff of 85 was used to eliminate pixels with an intensity of 0–84. Accordingly, CSC spurts with a high droplet density
(i.e., in a compact cloud) exhibit more reﬂection and thus a higher grayscale value. CSC spurts with a low droplet density (i.e., in a
diffuse cloud) have a lower reﬂection and thus a lower grayscale value. The generated clouds in the inserts therefore provide an
indication on the diffuseness or droplet distribution of a CSC spurt. Data modiﬁed from Aguilar et al.
2 The next set of experiments
(e–j) was performed on the skin of a healthy volunteer, showing frames from a CSC spray impingement video that corresponds to 0
(e), 32 (f), 64 (g), 100 (h), 128 (i), and 160 ms (j) during and after a 100-ms spurt at 254 mmHg hypobaric pressure. The distance
between the nozzle and the skin was 20 mm. The arrowheads in (e) and (j) indicate the transition from a concave to ﬂat skin surface
before and after the CSC spurt, respectively. Data modiﬁed from Aguilar et al.
2.
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window-chamber model as an in vivo platform
19,25,30,76
to evaluate phototherapies designed to eliminate
aberrant blood vessels. Based on data collected from
over 300 experiments, it was shown that, in the absence
of complete acute photocoagulation of the irradiated
vessels, the laser-irradiated region of interest (ROI)
remains perfused. These ﬁndings provided compelling
evidence for the supposition that complete acute pho-
tocoagulation of PWS vessels to a certain dermal
depth may be important to achieve optimal blanching,
as has been addressed earlier in clinical studies.
48,72
Purpura formation (local hemorrhage due to laser-
induced vascular damage) is typically used as a quali-
tative clinical endpoint and prognostic indicator for
photocoagulation. However, the extent of purpura
formation is not an unequivocally accurate indicator of
treatment outcome. In an exemplary computational
modeling study, Pfefer et al.
114 demonstrated that
incomplete thermal damage to superﬁcial PWS vessels
readily occurs because of a shielding phenomenon.
Speciﬁcally, the presence of PWS vessels proximal to
the skin surface will reduce the optical ﬂuence available
in any vessels directly below, thus reducing the prob-
ability of complete vessel photocoagulation. In this
case, purpura formation due to photocoagulation of
the proximal vessels is expected to occur, but the de-
gree of lesion blanching is expected to be compromised
because of incomplete photocoagulation of the opti-
cally shielded vessels. Furthermore, in our clinical
practice, we have observed signiﬁcant lesional
blanching at minimal purpura formation.
Based on the hypothesis that complete acute pho-
tocoagulation must be achieved and the problems with
using the purpura threshold as a metric of photoco-
agulation, a clinic-friendly laser speckle imaging (LSI)
system was developed
25,30,76 to assess the degree of
photocoagulation achieved during laser surgery. This
method would enable clinicians to visualize the degree
of skin perfusion after laser therapy as a means to
gauge the necessity of immediate retreatment of spe-
ciﬁc regions in which perfusion had persisted.
The LSI methodology has been described by Boas
and Dunn.
23 In summary, coherent light from typically
633-nm HeNe or 785-nm diode lasers is used to illu-
minate a ROI. A CCD or CMOS camera is used to
image the illuminated ROI, whereby a speckle pattern
is observed. Local ﬂuctuations in the speckle pattern
occur because of motion of optical scatterers such as
erythrocytes. When the image exposure time is greater
than a characteristic ﬂuctuation frequency of the
scatterers, local blurring of the speckle pattern occurs.
Subsequently, a local speckle contrast value (K)i s
calculated for each pixel using various algo-
rithms.
28,42,118,121 K is high when the degree of local
blurring is low (i.e., stationary scatterers), and K is low
when the degree of local blurring is high (i.e., moving
scatterers) (Fig. 6). Based on the assumptions made
about the motion characteristics (e.g., Brownian, or-
dered) of the moving scatterers, estimates of the
speckle decorrelation time (sc) are made from the K
value. The relative degree of scatterer motion, which is
referred to as the speckle ﬂow index (SFI), is assumed
to be the reciprocal of sc.
A primary design consideration during the devel-
opment of the LSI instrument was the ability to collect
raw speckle images with the patient positioned as
comfortably as possible. To this end, an articulated
arm was used as the base platform to provide ﬂexibility
in instrument positioning.
73 Continuous wave light
emitted from a 633-nm HeNe laser was delivered to the
ROI with an optical ﬁber, and a diffusing glass sub-
strate attached to the ﬁber output was used to
homogenize the emitted beam. Raw speckle reﬂectance
images were collected with a 12-bit, thermoelectrically
cooled CCD camera (2000R, QImaging, Burnaby,
FIGURE 6. The local speckle contrast changes due to scatterer motion. A 633-nm HeNe laser was used to irradiate two identical
white silicone blocks (the black vertical rectangle is the gap between the two blocks). (a) When both blocks are stationary, a
speckle pattern is visualized for both blocks. (b) When the left block is manually moved, the speckles become blurred, which
concurs with a reduction in speckle contrast (K). The lower the value of K, the higher the degree of scatterer motion (i.e., ﬂow when
employed on the skin, where erythrocytes comprise the scatterers).
AGUILAR et al. 494Canada) with a sensor size of 1600 9 1200 (H 9 W)
pixels. Image data were transferred to a PC for storage,
processing, and visualization. Custom-written Lab-
VIEW software was used to control all aspects of
image acquisition and processing. With a macro lens
attached to the camera, the size of the ROI was
4 9 3 cm.
The initial data collection focused on LSI performed
outside of the operating room.
73,74 Raw speckle
reﬂectance image sequences were collected before and
~40 min after treatment was completed. Based on a
pilot study involving measurements from 76 sites on 20
subjects, we observed that a decrease in skin perfusion
occurred at a lower-than-expected rate (72%), and that
regions of persistent perfusion were frequently present
(44%) (Fig. 7), which underscored the need for
objective blood ﬂow assessment during laser surgery of
PWSs.
Next, we developed a second-generation, clinic-
friendly LSI instrument encompassing the following
engineering aims: (1) blood ﬂow images should be
displayed in real time and (2) the instrument should
operate without perturbing the standard course of la-
ser treatment. To achieve aim 1, we designed software
that enabled speckle contrast and SFI calculations to
be performed on a graphics processing unit (GPU)
card,
162 which enabled real-time LSI of blood ﬂow. To
achieve aim 2, we developed a tripod-based LSI
instrument that is easy to position before laser treat-
ment and easy to reposition during surgery (Fig. 8a).
FIGURE 7. (a) Cross-polarized color image of a patient with a faint PWS. The black rectangle delineates the region imaged with
LSI. SFI maps, which indicate relative ﬂow velocities according to the indexed color (scale bar), were collected before (b) and
40 min after completion of laser treatment with a 595-nm pulsed dye laser. Some of the regions that had been irradiated exhibited
persistent perfusion, indicating incomplete photocoagulation of the PWS vasculature. Images adapted from Huang et al.
73.
FIGURE 8. (a) Schematic representation of the second-generation LSI instrument currently in use in the operating room during
laser surgery of PWSs. SFI images were extracted from a real-time video feed taken before (b) and at various stages during laser
surgery of a PWS: (c) after completion of alexandrite laser therapy, (d) after one pass of a 595-nm pulsed dye laser, (e) after a
subsequent pass of the 595-nm pulsed dye laser.
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immediate visual feedback on the degree of photoco-
agulation achieved at any perioperative time point. A
case study is presented in Figs. 8b–8e for illustrative
purposes. A patient with a PWS on the left side of her
face was treated initially with a 755-nm alexandrite
laser, followed by treatment with a 595-nm pulsed dye
laser. After treatment with the alexandrite laser, a
slight reduction in blood ﬂow was observed, with a
surrounding region of hyperemia. A hyperemic region
is frequently observed and is attributed to compensa-
tory vasodilation of the intact vasculature in part due
to thermoregulation. Following treatment with the
pulsed dye laser, a marked reduction in blood ﬂow was
observed, with some regions of persistent perfusion. A
subsequent pass with the pulsed dye laser resulted in
homogeneous shutdown of blood ﬂow in the treated
region. A clinical study is currently underway to
determine whether immediate retreatment on the basis
of LSI proﬁles leads to a signiﬁcant improvement in
treatment outcome.
SITE-SPECIFIC PHARMACO-LASER THERAPY
Endovascular Laser–Tissue Interactions in Incompletely
Photocoagulated Vessels
The concept of SP was developed around the
photothermal response, namely, the formation of a
thermal coagulum due to supracritical heat generation
in the vascular lumen with laser light. Complete pho-
tocoagulation of blood vessels is exclusively associated
with the photothermal component of endovascular
laser–tissue interactions, i.e., photocoagulation. How-
ever, in incompletely photocoagulated blood vessels,
i.e., blood vessels in refractory PWSs, the photothermal
FIGURE 9. The photothermal and hemodynamic responses studied in hamster dorsal skin fold venules.
19,68 The venules,
delineated by yellow dots in the upper left panel, were irradiated with a frequency-doubled Nd:YAG laser (532 nm, radiant exposure
of 289 J/cm
2, 30-ms pulse duration, and a spot size of 2.3 3 10
23 mm
2) to generate subocclusive thermal coagula. Endovascular
events were imaged by intravital ﬂuorescence microscopy in combination with brightﬁeld microscopy (photothermal response
only). The photothermal response (top row) encompassed the formation of a thermal coagulum (encircled) that remained attached
(not shown) or dislodged at the site of laser irradiation. The thermal coagulum was imaged in time, indicated in the upper right
corner. Thermal coagula were given a pseudocolor from the third panel onward for better visualization, obtained by intensity
thresholding. The second and third panels from the left are identical to demonstrate the accuracy with which the thermal coagula
were contoured. Fluorescent microspheres (bright dots in the venule) were infused to monitor blood ﬂow. Venular occlusion was
never achieved at these laser parameters, corresponding to the endovascular damage proﬁle in refractory PWS vessels. The
hemodynamic response was studied following ﬂuorescent labeling of platelets with 5(6)-carboxyﬂuorescein (5(6)-CF)
69 in vivo and
after laser irradiation (baseline, BSLN). The time after laser irradiation is provided in the upper left or right corner (min:s), and the
thermal coagulum is indicated by the arrow. Thrombosis, which encompassed platelet aggregation at and around the thermal
coagulum, was characterized by a growth phase (BSLN—06:15) and a subsequent deterioration phase (06:15–15:00). It was further
shown that the aggregating platelets become activated, as evidenced by the positive staining with ﬂuorescently labeled anti-
CD62P (P-selectin) antibodies, an activation-dependent epitope on platelets and endothelial cells (‘‘CD62P-FITC’’ row). Moreover,
the involvement of the coagulation cascade was conﬁrmed in experiments in which platelets were stained with 5(6)-CF and
heparin, an inhibitor of coagulation, was co-infused (‘‘5(6)-CF + HEP’’ row). The presence of heparin reduced the mean maximum
lesional size by 51% and signiﬁcantly reduced the duration of the thrombus growth phase.
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dynamic response (thrombosis).
64,68,140 The hemody-
namic response requires residual blood ﬂow for the
supply of platelets and coagulation factors, which is
absent in completely photocoagulated vasculature.
Recent in vivo studies have demonstrated that the
hemodynamic response entails both primary (platelet
adhesion, activation, and aggregation) and secondary
hemostasis (coagulation), and that the hemodynamic
response manifests itself even in the absence of a ther-
mal coagulum. The photothermal and hemodynamic
responses are summarized in Fig. 9
19,68,69 and lie at the
basis of site-speciﬁc pharmaco-laser therapy (SSPLT).
Principles of Site-Speciﬁc Pharmaco-Laser Therapy
SSPLT is a development stage treatment modality
that combines conventional laser therapy, SP, with the
prior systemic administration of prothrombotic and/or
antiﬁbrinolytic pharmaceutical agents encapsulated in
a targeted drug delivery system (DDS). The underlying
principles of SSPLT are based on the ﬁnding that
thrombosis constitutes an inherent component of en-
dovascular laser–tissue interactions in incompletely
coagulated vessels. With complete vascular occlusion
as the primary goal of SP, the hemodynamic response
may be used as a means to occlude vascular lumens
that have not been completely thermolysed during SP.
In this respect, manipulating the hemodynamic
response by the administration of prothrombotic and/
or antiﬁbrinolytic pharmaceuticals may function as an
adjuvant in complementing an inadequate endovascu-
lar damage proﬁle in refractory PWSs.
64,65,68 The
envisaged pharmacodynamics of SSPLT are illustrated
in Fig. 10 in the context of the photothermal and
hemodynamic response.
Drug Delivery Platform for Site-Speciﬁc
Pharmaco-Laser Therapy
The potential hazard of parentally administering
prothrombotic and/or antiﬁbrinolytic substances to
non-coagulopathic patients is impairment of the
FIGURE 10. Mechanistic illustration of the envisaged treatment modality. A PWS blood vessel is depicted on the left and the y-
axis represents its vascular diameter. The bottom of the y-axis indicates 0% occlusion, the top of the y-axis represents 100%
occlusion. The x-axis represents time, which is divided in a photothermal response time frame (i.e., laser irradiation) and a
hemodynamic response time frame (thrombosis and ﬁbrinolysis). When a patient with a recalcitrant PWS is treated with a laser
(pulse 1, yellow arrow), the blood vessel is only partially occluded by photocoagulated blood (thermal coagulum, black line). The
laser irradiation triggers thrombosis (green upward line), which extends the degree of vascular occlusion, but not to the level of
complete occlusion. Moreover, in time the thrombus breaks down because of enzymatic deterioration (ﬁbrinolysis, green down-
ward line). In case of site-speciﬁc pharmaco-laser therapy, photoactivatable nanoparticulate drug delivery carriers are infused into
the patient that contain pharmaceutical agents to promote thrombus growth and inhibit thrombus breakdown. Once these drug
carriers have accumulated in the thrombus after the ﬁrst laser pulse, a second laser pulse (pulse 2, red arrow) is used to induce
drug release and subsequent pharmacological augmentation of thrombosis and deterrence of ﬁbrinolysis (hyperthrombo-
sis + antiﬁbrinolysis, green line). The extent of hyperthrombosis and antiﬁbrinolysis is exacerbated to such a degree that the entire
blood vessel becomes occluded, marking the therapeutic endpoint (i.e., good clearance).
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quently, the pharmaceutical eﬃcacy of the prothrom-
botic and antiﬁbrinolytic agents must be constrained to
the laser-treated birthmark region only so that the reg-
ulation of naturally occurring hemostatic events is not
compromised.
64 This can be achieved by encapsulating
the pharmaceutical agents into a DDS.
Liposomes as Drug Delivery System for Site-Speciﬁc
Pharmaco-Laser Therapy
For SSPLT, liposomes (nanoscopic fat droplets)
constitute the most advantageous carrier system be-
cause of their manipulatable attributes and their ability
to encapsulate hydrophilic and lipophilic molecules at
FIGURE 11. (a) Generic scheme of possible liposomal formulations for site-speciﬁc pharmaco-laser therapy. Liposomes are
nanoscopic fat droplets that consist of a bilayer of phospholipids and an inner aqueous compartment. The possible liposomal
formulations can be divided into four main categories: conventional liposomes, anionic liposomes, sterically stabilized liposomes,
and targeted liposomes. Each main category may encompass any of the following subcategories: (I) types of drugs: 1. hydrophilic
drugs (e.g., tranexamic acid); 2. hydrophobic drugs (e.g., photosensitizers); 3. functionalized hydrophobic drugs (e.g., function-
alized photosensitizers); 4. ions (e.g., calcium); (II) drug grafting methods: 5. (covalent) attachment to a component (phospho)lipid;
6. (covalent) attachment to an anchor molecule (e.g., cholesterol); 7. (covalent) attachment to a polymer side chain (e.g., poly-
ethylene glycol, PEG); 8. (covalent) attachment to a functionalized distal end of a polymer; (III) membrane composition: 9. phos-
phatidylcholines; 10. phosphatidylcholines with a molar fraction of anionic/cationic (phospho)lipids; (IV) methods of steric
stabilization: 11. single chain polymer (e.g., polyethylene glycol, PEG); 12. multichain polymer; 13. multiblock copolymer (e.g., di-
or triblock copolymers); 14. photocleavable polymers (e.g., PEGylated plasmalogens); 15. adsorbable polymers (onto anionic/
cationic membrane surface); (V) methods of targeting: 16. antibodies; 17. antibody fragments (e.g., Fab’ fragments); and 18.
peptides. The main categories are not mutually exclusive; e.g., sterically stabilized liposomes may contain anionic membrane
constituents as well as antibodies for targeting. (b) The gel-to-liquid crystalline phase transition of a lipid bilayer. Lipid bilayers
principally exist in a gel phase (Lb) at temperatures (T) below phase transition temperature (Tm) and in a liquid crystalline phase (La)
at T>Tm, depicted on the x-axis. Lipid packing is highly ordered in Lb and somewhat disordered in La, accounting for the high and
lower degree of membrane impermeability, respectively. The maximum in several physical properties and characteristics, such as
(all on y-axis) speciﬁc heat, membrane permeability, and interphase boundary (between the melted liquid phase and still solid gel
phase) are all at a maximum at Tm, and deﬁne Tm. During heating, grain boundaries arise in the bilayer that demarcate lipid domains
in Lb and La (gray and white areas in top panels, respectively). The Lb–La interface is characterized by lipid packing defects that
impose signiﬁcant membrane permeability during which the release of liposome-encapsulated molecules becomes possible.
Figure partially adapted from Needham et al.
103 (c) Diagram of dipalmitoyl phosphocholine (16:0) in Lb (left molecule) transiting to
La (right molecule). The horizontal solid line marks the midplane of the bilayer. The ﬁgure is a superimposable representation at the
molecular level of the thermogram/phase diagram in (b). The hydrocarbon chains of the Lb phospholipid are in an all-trans state
before Tm. Following phase transition into La, the hydrocarbon chains exhibit considerable rotameric disorder that is characteristic
of linear alkyl chains at T>Tm. The thinning of the membrane is shown by DI 5 Ib 2 Ia , and the molecular areas Ab (gel phase) and
Aa (liquid crystalline phase) are indicated, all contributing to the increased permeability of the bilayer and corollary release (d,
arrows) of encapsulated molecules (d, black spheres). (c) Adapted from Nagle JF.
102.
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87). In addition to the inher-
ent non-to-very-low toxicity of neutral phospholip-
ids,
26,98 liposomes can be modiﬁed compositionally to
facilitate the unique prerequisites of the DDS.
Enhancement of the in vivo circulation time can be
accomplished by proper sizing
13 and by the conjuga-
tion of polyethylene glycol (PEG) to polar phospho-
lipids, usually phosphatidylethanolamine.
4,81,112,127
Inclusion of PEG chains is also useful for designing
immunotargeting liposomes capable of homing to the
target site through the attachment of antibodies or
Fab’ fragments to a chemically modiﬁed distal end of a
liposome-grafted PEG chain.
62,129,141,142 Antibodies
directed against platelet epitopes such as P-selectin,
which was shown to be expressed but not to play
a role in laser-induced thrombosis,
68 or antibodies
against ﬁbrin are suitable candidates for SSPLT of
PWSs.
FIGURE 12. (a) Model liposomal DDS for prothrombotic site-speciﬁc pharmaco-laser therapy, consisting of phosphatidylcholine
lipids, cholesterol, and a molar fraction of phosphatidylethanolamine-conjugated PEG. The PEG can be used to conjugate anti-
bodies for immunotargeting to the laser-induced thrombus via e.g., P-selectin or ﬁbrin. The liposomes encapsulate a second
generation photosensitizer, zinc phthalocyanine (ZnPC, red diamonds), in the lipid bilayer. The chemical structure of ZnPC is
provided in (b). (c) ZnPC is activated by irradiation with resonant light (absorption maximum at 674 nm), causing electrons to transit
from the ground (S0) to the ﬁrst excited state (S1) and subsequently to the triplet state (T1). The photodynamic effect proceeds from
the T1 state via energy transfer (type II) to molecular oxygen, yielding the highly cytotoxic and thrombogenic singlet oxygen (
1O2), a
ROS. The generation of ROS is shown in (d), where ZnPC-encapsulating liposomes composed of 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC, 66 mol%), cholesterol (30 mol%), and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-PEG (DSPE-PEG,
4 mol%) were suspended in buffer containing protonated dichloroﬂuorescein (DCFH2), a probe that becomes highly ﬂuorescent
upon oxidation (DCFH2 ﬁ DCF, kex 5 500 6 5 nm, kem 5 522 6 5 nm). The liposome suspension was irradiated with a 670-nm
solid-state diodelaser (hv, blue arrow) to activateZnPC. The formation of DCF wasmonitored by ﬂuorescence spectroscopy in time-
based acquisition mode. Oxidation of DCFH2 occurred immediately upon laser irradiation of ZnPC-liposomes (red trace, ZnPC:lipid
ratio of 0.004), as evidenced by the increase in DCF ﬂuorescence at 522 nm. Irradiation of ZnPC-lacking liposomes (control, black
trace) did not result in the generation of ROS and thus DCF ﬂuorescence. In (e), a similar setup was used as in (d) to demonstrate
ROS-mediated membrane disruption in cell phantoms composed of DPPC (39 mol%), distearoylphosphocholine (10 mol%), cho-
lesterol (20 mol%), dipalmitoylphosphoserine (20 mol%), dioleoylphosphocholine (5 mol%), 1-stearoyl-2-docosahexaenoylpho-
sphocholine (5 mol%), and 1 mol% a-tocopherol (5 mM ﬁnal lipid concentration). The ZnPC liposomes encapsulated calcein at a
self-quenching concentration (53 mM, kex 5 488 6 5 nm, kem 5 522 6 5 nm) in the aqueous compartment. Disruption of the lipo-
somal membrane results in leakage of calcein from the liposomes, abrogation of ﬂuorescence quenching, and increase in calcein
ﬂuorescence. At t 5 1 min, liposomes (lipos, blue arrow) were added to the cuvette in the ﬂuorescence spectrometer, at t 5 3 min
the suspension was irradiated with a 670-nm laser (hv, blue arrow), and at t 5 6 min Triton X-100, a detergent that solubilizes the
liposome membrane, was added (TX100, blue arrow) to determine complete calcein release from the liposomes. Irradiation of ZnPC-
encapsulating liposomes (red trace) resulted in rapid leakage of calcein from the liposomes, probably due to oxidative modiﬁcation
of phospholipids, whereas irradiation of ZnPC-lacking liposomes had no effect on membrane permeabilization. In (f) it is shown that
the ROS produced by ZnPC liposomes have the ability to oxidize amino acid residues in bovine serum albumin (BSA). A similar
experiment was performed as in (d), only the ZnPC-liposomes were suspended in buffer containing BSA. The ﬂuorescence of
tryptophan (kex 5 280 6 5 nm, kem 5 360 6 5 nm), an autoﬂuorescent amino acid in BSA, was measured as a function of time.
Oxidation of tryptophan leads to abrogation of ﬂuorescence. At t 5 2 min, the liposome-containing cuvette was irradiated with 670-
nm light (hv, blue arrow). Oxidation of tryptophan occurred in samples containing ZnPC-liposomes (red trace) but not in samples
containing ZnPC-lacking liposomes (black trace), as evidenced by the rapid reduction in ﬂuorescence intensity. Data were nor-
malized to tryptophan ﬂuorescence at t 5 1.99 min. The data in panels (e, f) comprise mean 6 SD traces from n 5 3 experiments
(ZnPC-liposomes) and single traces for control liposomes. All data is unpublished.
An Overview of Three Promising Mechanical, Optical, and Biochemical Engineering Approaches 499An additional beneﬁt of liposomal DDSs is that the
drug release mechanism can be accommodative to the
speciﬁc application and physiological context. Active
triggering mechanisms can be engineered around
thermosensitivity (membrane destabilization through
kineticenergy)
10,103(Figs. 11b–11d
102,103),photochemi-
cal modiﬁcation of bilayer structure,
54,131 or a combi-
nation thereof. Hyperthermia has been employed in
numerous liposomal formulations in vitro and in
vivo
10,17,50,51,82,97,99,103,158 to initiate a thermotropic
alteration in membrane permeability that will lead to a
rapid, triggered release of the loaded molecules.
Diﬀerent liposomal formulations will be employed
for the prothrombotic and the antiﬁbrinolytic SSPLT
modalities. Principally, both liposomal formulations
consist of dipalmitoyl phosphocholine (DPPC), contain
a 4% molar fraction of PEG-conjugated distearoyl
phopshoethanolamine (DSPE-PEG), and are targeted
to thrombi in partially occluded PWS vasculature
through. e.g., the conjugation of thrombus-speciﬁc
antibodies. However, liposomes for prothrombotic
SSPLT encapsulate a photosensitizer in the lipid bilayer
that ampliﬁes the hemodynamic response by reactive
oxygen species (ROS) following activation of the pho-
tosensitizer by resonant light. Contrastingly, liposomes
for antiﬁbrinolytic SSPLT are thermosensitive and
contain an antiﬁbrinolytic agent in the aqueous com-
partment that is actively released upon a heat stimulus.
Liposomes for Prothrombotic Site-Speciﬁc Pharmaco-
Laser Therapy
Rather than using classical prothrombotic agents,
which typically are expensive and heat-labile proteins,
the prototype liposomal DDS for prothrombotic
SSPLT contains zinc phthalocyanine (ZnPC), a second
FIGURE 13. (a) Model liposomal DDS for antiﬁbrinolytic site-speciﬁc pharmaco-laser therapy, consisting of 1,2-dipalmitoyl-sn-
glycero-3-phosphocholine (DPPC, 96 mol%) and a molar fraction of polyethylene glycol-conjugated 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine (DSPE-PEG, 4 mol%). The phase transition temperature (Tm) of this formulation is 42.3  C, i.e., ~5  C above
body temperature. The PEG can be used to conjugate antibodies for immunotargeting to the laser-induced thrombus via e.g., P-
selectin or ﬁbrin. The liposomes encapsulate tranexamic acid (TA, green circles) in the aqueous compartment. The chemical
structure of TA is provided in (b). (c) Mechanism of ﬁbrinolysis and inhibitory pathways in the context of laser-induced thrombosis.
Plasminogen is converted to plasmin by tissue-type plasminogen activator (tPA), which cleaves cross-polymerized ﬁbrin strands
in the thrombus, resulting in the generation of ﬁbrin degradation products and embolization. Plasminogen activator inhibitor-1
(PAI-1) inhibits the conversion of plasminogen to plasmin, alpha-2 antiplasmin (a-2-AP) and thrombin-activatable ﬁbrinolysis
inhibitor (TAFI) antagonize the enzymatic activity of plasmin, and TA inhibits plasmin(ogen) at the lysine binding sites. The
liposomes described in (a) were prepared with 316 mM TA and assayed for heat-induced drug release. (d) Heat-induced release
kinetics of TA from thermosensitive liposomes measured near Tm and 4  C below Tm (control) in buffer (10 mM HEPES, 0.88% NaCl,
pH 5 7.4, 0.292 osmol/kg). Near-complete TA release was achieved within 2.5 min of heating at 43.3  C, whereas heating at 39.3  C
resulted in ~13% TA release after 5 min (unpublished results). In (e), heat-induced TA release from thermosensitive liposomes was
measured in whole blood,
75 exhibiting comparable TA release kinetics as in buffer.
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s. 12a and 12b). Photosensitizers are compounds that,
upon excitation to triplet state by resonant light,
undergo electron transfer (type I) or energy transfer
(type II) reactions with molecular oxygen to form ROS
(Fig. 12c). The generation of these reactive transients
leads to irreversible modiﬁcation of biomolecules and,
when generated in the circulation, to platelet
45,46 and
endothelial cell damage/activation
63,101,157 and sub-
sequent thrombosis.
91,123 Consequently, incorporation
and photo-activation of ZnPC-liposomes in laser-in-
duced thrombi is expected to result in exacerbation of
the hemodynamic response and ultimately complete
occlusion of otherwise incompletely photocoagulated
vascular lumens. In vitro experiments have revealed
that liposomes composed of DPPC:cholesterol:DSPE-
PEG (66:30:4 mol ratio) encapsulating ZnPC at a
0.004 photosensitizer:lipid ratio are capable of gener-
ating ROS (Fig. 12d), induce perturbations in lipid
bilayers (Fig. 12e), and oxidize amino acid residues in
proteins (Fig. 12f). These data, albeit preliminary,
have established proof-of-concept and support the
postulation that hypertrombosis can be achieved with
this liposomal DDS by photochemical means.
Liposomes for Antiﬁbrinolytic Site-Speciﬁc
Pharmaco-Laser Therapy
Given the thermal nature of endovascular laser–tis-
sue interactions, the triggering mechanism of the rudi-
mentary antiﬁbrinolytic DDS was designed around
thermosensitivity. The DDS for antiﬁbrinolytic
SSPLT therefore comprises thermosensitive liposomes
(Figs. 11b–11d
102,103) that encapsulate tranexamic acid
(TA) in the aqueous compartment (Fig. 13a). TA is an
antiﬁbrinolyticagent(Fig. 13b)thatiswidelyusedinthe
clinical setting for a variety of bleeding-deterrent pro-
cedures.
78,89,96,128,161 TA completely antagonizes the
biological activity of plasmin(ogen) by occupying its
lysine binding sites
135 (Fig. 13c). Plasmin, which is
gradually formed with the onset of coagulation, is
responsible for cleaving cross-polymerized ﬁbrin
strands that make up the reticular network of the
thrombus.
108 The absence of ﬁbrinolysis by the inhibi-
tory effect of TA will therefore preserve thrombus
integrity and promote thrombus stability during and
after laser-induced thrombus formation, delaying
gradual thrombus dissolution as a result of ﬁbrinolysis
and shear stress.
TA-encapsulating liposomes composed of
DPPC:DSPE-PEG in a 96:4 mol ratio have been pre-
pared and characterized.
66,67 These liposomes exhibit a
phase transition maximum at 42.3  C, which is approx-
imately 5  C above body temperature and therefore
presumedsafeforuseinpatientswithPWSsbutwithout
any coagulopathies. Preliminary in vitro experiments
have demonstrated that almost complete release of TA
from thermosensitiveliposomesinbufferedsolutioncan
be achieved within 2.5 min of heating near the phase
transition temperature (43.3  C), whereas minimal TA
release occurs at temperatures slightly above body tem-
perature (39.3  C) (Fig. 13d
66,67). Similarly, TA-lipo-
somes suspended in whole blood exhibit similar release
kinetics as the buffer-suspended liposomes when heated
at 43.3  C( Fig. 13e),
75 indicating that plasma compo-
nents do not detrimentally impact heat-induced TA re-
leaseinphysiologicalﬂuids.
37,61,125Thecurrentlackofin
vivoproof-of-conceptnotwithstanding,thedataprovide
compelling evidence for the potential efﬁcacy of antiﬁ-
brinolytic intervention in laser-treated, partially oc-
cluded PWS vasculature.
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